OREGON: OLCC Notice of Public Hearing.
What: OAR 845-025-5760, Audit, Compliance, and Random Testing
When: 2:00 p.m. – 3:00 p.m., Monday, March 16, 2020
Where: Oregon Liquor Control Commission, 9079 SE McLoughlin Blvd., Portland, OR 97222
The national outbreak of e-cigarette or vaping product use-associated lung injury (EVALI) has resulted in more than 2,800 hospitalizations and 68 deaths, including 2 deaths in Oregon. At this time neither the Centers for Disease Control and Prevention (CDC), the Federal Food and Drug Administration (FDA), nor the Oregon Health Authority (OHA) have determined the cause of the illness outbreak in Oregon. While studies using cases in other states have identified Vitamin E acetate as one likely cause in those states, there is no evidence of Vitamin E acetate being linked to cases in Oregon and the CDC and FDA have not ruled out other potential causes of the illness outbreak.
This rule is needed to assist the OLCC and OHA in the ongoing investigation of the cause of EVALI cases in Oregon as well as to prevent and respond to potential future outbreaks or risks to public safety due to additives, adulterants, microbiological contamination, heavy metals, or other contaminants.
In addition to the recent EVALI outbreak, undisclosed ingredients and additives have been discovered in marijuana products in violation of Commission rules. These ingredients and additives cause public health and safety issues and decrease transparency for members of the public using these products. These rule amendments will allow the OLCC to sample the products of marijuana licensees to determine whether they contain ingredients or additives. Further, the ability to randomly test acts as a deterrent and discouraging licensees from making marijuana items with illegal or unknown indigents, additives, solvents or pesticides.
Public comment period ends Sunday, March 22, 2020 at 11:55PM